High lumbar skeletal muscle quality may potentially be used to predict the therapeutic effects of PD‐1/PD‐L1 inhibitors, independent of PS and PD‐L1 expression, in patients with advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.